Portfolio
October 22, 2024

Benchling acquires PipeBio to accelerate AI-powered antibody discovery

Our portfolio company, PipeBio, has been acquired by Benchling. The acquisition brings together Benchling’s leadership in cloud-based R&D software with PipeBio’s expertise in high-throughput bioinformatics, driving future innovation in biologics discovery.

No items found.
Benchling acquires PipeBio to accelerate AI-powered antibody discovery
More about the author(s)
No items found.
More about the author(s)
No items found.